Zydus Cadila has introduced a generic version of Remdesivir, branded as Remdac, at the cost of Rs 2,800 per 100 mg vial in India. This move aims to provide a cost-effective treatment solution for patients with severe COVID-19 symptoms. The company, in a regulatory filing, highlighted that Remdac is the most economical Remdesivir brand available in the Indian market. This initiative aligns with Zydus Cadila’s commitment to ensuring accessibility to critical medications for COVID-19 treatment.
By leveraging its distribution network, Zydus Cadila plans to make Remdac widely available across India, catering to both government and private hospitals treating COVID-19 patients. The manufacturing of the active pharmaceutical ingredient (API) for Remdac occurs at the company’s API facilities in Gujarat, showcasing complete backward integration that contributes to its affordability. This strategic approach has positioned Remdac as a competitive offering in the Remdesivir landscape.
Zydus Cadila’s collaboration with Gilead Sciences to produce and distribute Remdesivir further strengthens its foothold in the pharmaceutical market. The emergency use authorization granted by the USFDA for Remdesivir underscores its significance in treating severe COVID-19 cases. Moreover, Zydus Cadila is actively engaged in developing a vaccine, ZyCov-D, which has progressed to phase-II clinical trials, reflecting its dedication to combating the pandemic comprehensively.
The launch of Remdac cements Zydus Cadila’s position as the fifth company to introduce a generic version of Remdesivir in India. This competitive environment benefits patients by offering a variety of options at different price points. The significance of such initiatives becomes evident amidst the backdrop of the rising COVID-19 cases in India. Zydus Cadila’s commitment to affordable healthcare solutions aligns with its overarching goal of supporting public health during these challenging times.
Key Takeaways:
– Zydus Cadila’s introduction of Remdac at a competitive price of Rs 2,800 per vial aims to make Remdesivir more accessible for COVID-19 patients in India.
– The company’s complete backward integration strategy contributes to Remdac being the most economical Remdesivir brand in the country.
– Zydus Cadila’s ongoing efforts in vaccine development and clinical trials showcase its holistic approach to addressing the healthcare needs arising from the pandemic.
– The pharmaceutical landscape in India benefits from the healthy competition among companies introducing generic versions of essential drugs like Remdesivir, ultimately benefiting patients in need.
Tags: regulatory
Read more on businessworld.in